Table 3.
Results of the cost-effectiveness analysis
| Sofosbuvir | Comparators | |
|---|---|---|
| Nonactualized | ||
| Cost of treatment | 67 291 € | 24 186 € |
| Cost of care | 7239 € | 23 772 € |
| Total cost | 74 531 € | 47 958 € |
| Life expectancy (years) | 33.8 | 30.2 |
| Quality adjusted life expectancy (QALY) | 22.9 | 19.4 |
| Actualized | ||
| Total cost | 72 213 € | 39 789 € |
| Life expectancy (years) | 22.3 | 20.4 |
| QALY | 15.0 | 13.0 |
| Sofosbuvir versus Comparators | ||
| Incremental cost | 32 423 € | |
| Incremental life expectancy | 1.8 | |
| Incremental QALY | 2.0 | |
| ICER (life expectancy) | 17 817 €/LY | |
| ICER (QALY) | 16 278 €/QALY | |
ICER: Incremental Cost–Effectiveness Ratio, LY: Life Year.